Compumed - 500 Beiträge pro Seite
eröffnet am 03.04.07 18:08:48 von
neuester Beitrag 21.07.07 16:41:35 von
neuester Beitrag 21.07.07 16:41:35 von
Beiträge: 17
ID: 1.122.569
ID: 1.122.569
Aufrufe heute: 0
Gesamt: 1.491
Gesamt: 1.491
Aktive User: 0
ISIN: US2049145012 · WKN: A3DL9V · Symbol: CMPD
1,5900
USD
-6,47 %
-0,1100 USD
Letzter Kurs 15.04.24 Nasdaq OTC
Neuigkeiten
12.03.24 · Accesswire  |
24.10.23 · Accesswire |
12.06.23 · Accesswire |
25.05.23 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0400 | +48,57 | |
| 12,810 | +39,69 | |
| 0,5400 | +38,46 | |
| 27,80 | +32,38 | |
| 31,00 | +24,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6610 | -24,02 | |
| 0,7350 | -31,31 | |
| 28,18 | -32,62 | |
| 0,5660 | -40,42 | |
| 2,8100 | -48,72 |
Feedback
Was soll man von diesem Deal halten! Kommentare erwünscht!
(Aus dem RB-Board)
Compumed ist in der Medizintechnik bzw. Software tätig www.compumed.net
Effectively, CMPD Has Sold 1/3rd of the Company...
...to Boston Avenue Capital, LLC.
+ 24,540,000 previous shares
+ 12,500,000 new shares & warrants
= 37,040,000
12,500,000 / 37,040,000 = 33.75%
Boston Avenue Capital, LLC Files Form SC 13D/A...
...This is more than just a simple investment:
Boston and Yorktown are Oklahoma limited liability companies whose principal business is business investment. VFA is an Oklahoma limited liability company whose principal business is investment management. Gillman, a U.S. citizen, is in the business of managing various investment entities.
The principal business office address of Boston, Yorktown, VFA and Gillman is 415 South Boston, 9 th Floor, Tulsa, Oklahoma 74103.
None of the entities or persons identified in this Item 2 has, during the past five years, been convicted of any criminal proceeding (excluding traffic violations or similar misdemeanors), nor been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
The source of funds for the purchases of securities was the working capital of Boston and Yorktown. The total consideration paid by Boston pursuant to the transaction indicated in Item 4 below was $2,000,000. The total consideration paid by Yorktown for all purchases was $19,084.50, including commissions and fees.
Item 4. Purpose of Transaction
Pursuant to the terms of a Securities Purchase Agreement (“Agreement”), dated as of March 12, 2007, between Boston and Issuer, Boston acquired 4,167 Units in a private placement transaction (the “Boston Transaction”). Each Unit consists of 1 share of unregistered Class D 2% Convertible Preferred Stock (“Preferred Stock”) as well as 1,000 unregistered Common Stock Purchase Warrants (“Warrants”). Each share of Preferred Stock is convertible at any time into 2,000 shares of Common Stock with all of the Preferred Stock convertible into a total of 8,334,000 shares of Common Stock. The Warrants are exercisable at any time to purchase shares of Common Stock with all of the exercised Warrants equaling a total of 4,166,500 shares of Common Stock.
The purpose of the Boston Transaction is for investment, and the acquisition of the Units was made in the ordinary course of business and was not made for the purpose of acquiring control of the Issuer.
Although no Reporting Person has any specific plan or proposal to acquire or dispose of the Preferred Stock, the Warrants or the underlying Common Stock, as the case may be, consistent with its investment purpose, each Reporting Person at any time and from time to time may acquire additional Preferred Stock, Warrants or Common Stock or dispose of any or all of its Preferred Stock, Warrants or Common Stock depending upon an ongoing evaluation of the investment in the Preferred Stock, the Warrants and/or the Common Stock, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Persons, and/or other investment considerations.
Also, consistent with the investment purpose, the Reporting Persons may engage in communications with one or more shareholders of the Issuer, one or more officers of the Issuer and/or one or more members of the board of directors of the Issuer and/or one or more representatives of the Issuer regarding the Issuer, including but not limited to its operations. The Reporting Persons may discuss ideas that, if effected may result in any of the following: the acquisition by persons of additional Preferred Stock, Warrants or Common Stock of the Issuer, an extraordinary corporate transaction involving the Issuer, and/or changes in the board of directors or management of the Issuer.
Under the terms of the Agreement, Boston has the option to designate 3 non-voting observers to attend meetings of the Board of Directors of the Issuer for as long as the Boston owns any shares of the Preferred Stock, not to exceed 5 years from March 12, 2007. Additionally, 6 months following March 14, 2007, Boston may nominate one of the observers to become a member of the Board of Directors of the Issuer to serve a term of 2 years, after which time such member may be reelected by the shareholders of the Issuer in the same manner as any other director.
Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.
Item 5. Interest in Securities of the Issuer
(a), (b) According to the Issuer, there were 24,638,341 shares of Common Stock outstanding as of the date of the Agreement. As of the date of the original filing of this Schedule 13D, Yorktown directly owned 63,500 shares of Common Stock and Boston directly owned 12,500,500 shares of Common Stock through its ownership of Preferred Stock and Warrants which are convertible into Common Stock within 60 days of the date of filing. Such shares represent 33.8% of the Issuer’s outstanding shares of Common Stock (inclusive of the 12,500,500 shares underlying the Preferred Stock and Warrants) in accordance with Rule 13d-3(d)(1)(i)(D).
Although VFA and Gillman are joining in this Schedule as Reporting Persons, the filing of this Schedule shall not be construed as an admission that any of them are, for any purpose, the beneficial owner of any of the securities that are beneficially owned by Boston and Yorktown.
(c) During the last 60 days, the Reporting Persons did not purchase any shares of Common Stock in the open market.
(d) and (e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
Please see the discussion relating to the Agreement about board observers and the nomination of a board member in Item 4. Furthermore under the Agreement, for a period of 36 months from the closing date of the subject acquisition (March 14, 2007), Boston has the right of first refusal to participate in any private offering of the securities of the Issuer, including subscription rights, on the same terms as offered to other potential investors, and purchase securities up to an offering price of $5,000,000. Furthermore, as part of the Boston Transaction, the Issuer issued a finder’s fee, Common Stock Purchase Warrants to purchase 500,000 shares of Common Stock and also paid the finder a cash commission for serving as the agent for the private placement.
Other than the foregoing described Agreement, none of the Reporting Persons is a party to any contract, arrangement, understanding or relationship with respect to any securities of the Issuer.
(Aus dem RB-Board)
Compumed ist in der Medizintechnik bzw. Software tätig www.compumed.net
Effectively, CMPD Has Sold 1/3rd of the Company...
...to Boston Avenue Capital, LLC.
+ 24,540,000 previous shares
+ 12,500,000 new shares & warrants
= 37,040,000
12,500,000 / 37,040,000 = 33.75%
Boston Avenue Capital, LLC Files Form SC 13D/A...
...This is more than just a simple investment:
Boston and Yorktown are Oklahoma limited liability companies whose principal business is business investment. VFA is an Oklahoma limited liability company whose principal business is investment management. Gillman, a U.S. citizen, is in the business of managing various investment entities.
The principal business office address of Boston, Yorktown, VFA and Gillman is 415 South Boston, 9 th Floor, Tulsa, Oklahoma 74103.
None of the entities or persons identified in this Item 2 has, during the past five years, been convicted of any criminal proceeding (excluding traffic violations or similar misdemeanors), nor been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
The source of funds for the purchases of securities was the working capital of Boston and Yorktown. The total consideration paid by Boston pursuant to the transaction indicated in Item 4 below was $2,000,000. The total consideration paid by Yorktown for all purchases was $19,084.50, including commissions and fees.
Item 4. Purpose of Transaction
Pursuant to the terms of a Securities Purchase Agreement (“Agreement”), dated as of March 12, 2007, between Boston and Issuer, Boston acquired 4,167 Units in a private placement transaction (the “Boston Transaction”). Each Unit consists of 1 share of unregistered Class D 2% Convertible Preferred Stock (“Preferred Stock”) as well as 1,000 unregistered Common Stock Purchase Warrants (“Warrants”). Each share of Preferred Stock is convertible at any time into 2,000 shares of Common Stock with all of the Preferred Stock convertible into a total of 8,334,000 shares of Common Stock. The Warrants are exercisable at any time to purchase shares of Common Stock with all of the exercised Warrants equaling a total of 4,166,500 shares of Common Stock.
The purpose of the Boston Transaction is for investment, and the acquisition of the Units was made in the ordinary course of business and was not made for the purpose of acquiring control of the Issuer.
Although no Reporting Person has any specific plan or proposal to acquire or dispose of the Preferred Stock, the Warrants or the underlying Common Stock, as the case may be, consistent with its investment purpose, each Reporting Person at any time and from time to time may acquire additional Preferred Stock, Warrants or Common Stock or dispose of any or all of its Preferred Stock, Warrants or Common Stock depending upon an ongoing evaluation of the investment in the Preferred Stock, the Warrants and/or the Common Stock, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Persons, and/or other investment considerations.
Also, consistent with the investment purpose, the Reporting Persons may engage in communications with one or more shareholders of the Issuer, one or more officers of the Issuer and/or one or more members of the board of directors of the Issuer and/or one or more representatives of the Issuer regarding the Issuer, including but not limited to its operations. The Reporting Persons may discuss ideas that, if effected may result in any of the following: the acquisition by persons of additional Preferred Stock, Warrants or Common Stock of the Issuer, an extraordinary corporate transaction involving the Issuer, and/or changes in the board of directors or management of the Issuer.
Under the terms of the Agreement, Boston has the option to designate 3 non-voting observers to attend meetings of the Board of Directors of the Issuer for as long as the Boston owns any shares of the Preferred Stock, not to exceed 5 years from March 12, 2007. Additionally, 6 months following March 14, 2007, Boston may nominate one of the observers to become a member of the Board of Directors of the Issuer to serve a term of 2 years, after which time such member may be reelected by the shareholders of the Issuer in the same manner as any other director.
Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.
Item 5. Interest in Securities of the Issuer
(a), (b) According to the Issuer, there were 24,638,341 shares of Common Stock outstanding as of the date of the Agreement. As of the date of the original filing of this Schedule 13D, Yorktown directly owned 63,500 shares of Common Stock and Boston directly owned 12,500,500 shares of Common Stock through its ownership of Preferred Stock and Warrants which are convertible into Common Stock within 60 days of the date of filing. Such shares represent 33.8% of the Issuer’s outstanding shares of Common Stock (inclusive of the 12,500,500 shares underlying the Preferred Stock and Warrants) in accordance with Rule 13d-3(d)(1)(i)(D).
Although VFA and Gillman are joining in this Schedule as Reporting Persons, the filing of this Schedule shall not be construed as an admission that any of them are, for any purpose, the beneficial owner of any of the securities that are beneficially owned by Boston and Yorktown.
(c) During the last 60 days, the Reporting Persons did not purchase any shares of Common Stock in the open market.
(d) and (e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
Please see the discussion relating to the Agreement about board observers and the nomination of a board member in Item 4. Furthermore under the Agreement, for a period of 36 months from the closing date of the subject acquisition (March 14, 2007), Boston has the right of first refusal to participate in any private offering of the securities of the Issuer, including subscription rights, on the same terms as offered to other potential investors, and purchase securities up to an offering price of $5,000,000. Furthermore, as part of the Boston Transaction, the Issuer issued a finder’s fee, Common Stock Purchase Warrants to purchase 500,000 shares of Common Stock and also paid the finder a cash commission for serving as the agent for the private placement.
Other than the foregoing described Agreement, none of the Reporting Persons is a party to any contract, arrangement, understanding or relationship with respect to any securities of the Issuer.
Antwort auf Beitrag Nr.: 28.644.948 von koalabaer25 am 03.04.07 18:08:48Wird noch eine Weile dauern bis Boston Avenue Capital die Firma "umstrukturiert". Die Aktie hat zumindest kein Abwärtspotential. Ich überlege mir noch ein paar ins Depot zu legen. Eine Hedgefonds investiert nicht ins Blaue hinein.
http://www.compumed.com
http://www.compumed.com
Antwort auf Beitrag Nr.: 29.382.128 von koalabaer25 am 19.05.07 10:01:42Fehler Falsche Webseite!
Richtig: http://www.compumed.net
Richtig: http://www.compumed.net
Es tut sich was. 2 neue Direktoren. Immerhin schon mal ein Anfang.
Mal gucken was die Aktie heute so macht.
CompuMed, Inc. Adds Two New Board Members
Thursday May 24, 8:00 am ET
LOS ANGELES--(BUSINESS WIRE)--CompuMed, Inc. (OTCBB:CMPD - News) -- a medical informatics company leading the development of advanced imaging technology for cost effective analysis and monitoring -- today announced the appointment of Simon P. James, a consultant to Oaktree Capital Management, and Mark D. Stolper, executive vice president and chief financial officer of RadNet, Inc. (NASDAQ: RDNT - News), to its board of directors.
Jerry McLaughlin, CompuMed's chief executive officer, said, "I look forward to working closely with our new directors. We believe Mr. Stolper's in-depth knowledge of the imaging industry coupled with Mr. James' proven track record in international trade will bring new insights and experience to our Board of Directors that will ultimately benefit our shareholders."
Simon James is a consultant to Oaktree Capital Management, LLC, Principal Opportunities Fund. Prior to joining Oaktree in January 2005, Mr. James was an Associate Principal with McKinsey & Company, Inc., where he was responsible for developing, negotiating and leading complex strategic and operational turnarounds in a broad range of industries. Mr. James received a PhD in finance and a bachelor's degree in Natural Science from Cambridge University.
At Oaktree, Mr. James specializes on cross border opportunities - particularly those involving partnering with Chinese companies. Mr. James is also a board director of Wright Line, LLC., a leading manufacturer of technical furniture and datacenter enclosures and a portfolio company of Oaktree Capital.
Mark Stolper is the Chief Financial Officer of RadNet, Inc., a NASDAQ-listed leading owner and operator of medical diagnostic imaging centers. From January 2001 to July 2004, Mr. Stolper was a partner at Broadstream Capital Partners, LLC and West Coast Capital, a Los Angeles-based investment banking firm focused on advising middle market companies engaged in financing and merger and acquisition transactions. Prior to joining Broadstream, Mr. Stolper was responsible for business development and mergers and acquisitions for Eastman Kodak's entertainment companies and its online image licensing business, Picture Network International. Mr. Stolper has also served as a member of Archon Capital Partners, Dillon, Read & Co., Inc., and Saratoga Partners, LLP. Mr. Stolper graduated magna cum laude from the University of Pennsylvania and received a finance degree from the Wharton School.
Mr. Stolper has assisted RadNet in growing its revenue from $137 million to more than $400 million and has raised over $600 million of capital for the company. During this time, RadNet's market capitalization and stock price has expanded by more than 10 times. RadNet is leading owner and operator of freestanding medical diagnostic imaging centers in the U.S. with approximately 4,000 employees and 129 facilities in seven states. RadNet performs more than 2.5 million imaging exams each year.
Robert Stuckelman, CompuMed's chairman, said, "Our two new directors provide great strength and a clear understanding in areas where CompuMed intends to expand, including the radiology community where our OsteoGram can be coupled with the rapidly proliferating digital mammography systems. We expect that imaging centers will soon offer bone density screening in conjunction with mammography, since many women getting mammograms are also candidates for osteoporosis screening. In addition we are gaining a wealth of experience in strategic planning and international business."
Mal gucken was die Aktie heute so macht.
CompuMed, Inc. Adds Two New Board Members
Thursday May 24, 8:00 am ET
LOS ANGELES--(BUSINESS WIRE)--CompuMed, Inc. (OTCBB:CMPD - News) -- a medical informatics company leading the development of advanced imaging technology for cost effective analysis and monitoring -- today announced the appointment of Simon P. James, a consultant to Oaktree Capital Management, and Mark D. Stolper, executive vice president and chief financial officer of RadNet, Inc. (NASDAQ: RDNT - News), to its board of directors.
Jerry McLaughlin, CompuMed's chief executive officer, said, "I look forward to working closely with our new directors. We believe Mr. Stolper's in-depth knowledge of the imaging industry coupled with Mr. James' proven track record in international trade will bring new insights and experience to our Board of Directors that will ultimately benefit our shareholders."
Simon James is a consultant to Oaktree Capital Management, LLC, Principal Opportunities Fund. Prior to joining Oaktree in January 2005, Mr. James was an Associate Principal with McKinsey & Company, Inc., where he was responsible for developing, negotiating and leading complex strategic and operational turnarounds in a broad range of industries. Mr. James received a PhD in finance and a bachelor's degree in Natural Science from Cambridge University.
At Oaktree, Mr. James specializes on cross border opportunities - particularly those involving partnering with Chinese companies. Mr. James is also a board director of Wright Line, LLC., a leading manufacturer of technical furniture and datacenter enclosures and a portfolio company of Oaktree Capital.
Mark Stolper is the Chief Financial Officer of RadNet, Inc., a NASDAQ-listed leading owner and operator of medical diagnostic imaging centers. From January 2001 to July 2004, Mr. Stolper was a partner at Broadstream Capital Partners, LLC and West Coast Capital, a Los Angeles-based investment banking firm focused on advising middle market companies engaged in financing and merger and acquisition transactions. Prior to joining Broadstream, Mr. Stolper was responsible for business development and mergers and acquisitions for Eastman Kodak's entertainment companies and its online image licensing business, Picture Network International. Mr. Stolper has also served as a member of Archon Capital Partners, Dillon, Read & Co., Inc., and Saratoga Partners, LLP. Mr. Stolper graduated magna cum laude from the University of Pennsylvania and received a finance degree from the Wharton School.
Mr. Stolper has assisted RadNet in growing its revenue from $137 million to more than $400 million and has raised over $600 million of capital for the company. During this time, RadNet's market capitalization and stock price has expanded by more than 10 times. RadNet is leading owner and operator of freestanding medical diagnostic imaging centers in the U.S. with approximately 4,000 employees and 129 facilities in seven states. RadNet performs more than 2.5 million imaging exams each year.
Robert Stuckelman, CompuMed's chairman, said, "Our two new directors provide great strength and a clear understanding in areas where CompuMed intends to expand, including the radiology community where our OsteoGram can be coupled with the rapidly proliferating digital mammography systems. We expect that imaging centers will soon offer bone density screening in conjunction with mammography, since many women getting mammograms are also candidates for osteoporosis screening. In addition we are gaining a wealth of experience in strategic planning and international business."
Die beiden neuen Direktoren erhalten anscheinend viel Zuspruch. Ich bin froh, dass die Aktie aus Ihrer Lethargie erwacht. Die nächsten Wochen/Monate werden spannend.
Mal schaun ob ich Alleinunterhalte bleibe
.
Last Trade: 0.36
Trade Time: 3:35PM ET
Change: 0.08 (28.57%)
Prev Close: 0.28
Open: 0.28
Bid: 0.35 x 5000
Ask: 0.36 x 5000
1y Target Est: N/A
Day's Range: 0.28 - 0.37
52wk Range: 0.22 - 0.56
Volume: 592,990
Avg Vol (3m): 33,198.5
Market Cap: 8.86M
P/E (ttm): N/A
EPS (ttm): -0.03
Div & Yield: N/A (N/A)
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On May 17, 2007, we entered into a Side Letter Agreement with Boston Avenue Capital, LLC, amending the Securities Purchase Agreement between Boston Avenue Capital and us dated March 12, 2007. Under the terms of the Side Letter Agreement, within six months of the closing, Boston Avenue Capital has the right to recommend up to two nominees to be members of our Board of Directors.
Subject to the approval of the Board of Directors, the nominees shall be elected to serve a term of up to two years, after which, the Board of Directors may nominate them to be elected by the shareholders at the annual shareholder meeting in the same manner as any other director.
On May 17, 2007, we entered into an Agreement with Boston Avenue Capital, LLC.
The Agreement provides that Boston Avenue Capital and its affiliates will vote all of its stock in favor of the current Board of Directors for a period of five years.
On May 17, 2007, in connection with the Side Letter Agreement, the Board of Directors appointed Mr. Mark Stolper and Mr. Simon James as Directors. We intend for our new Board members to serve until their successors are duly nominated and elected.
As compensation for joining the Board of Directors, Mr. Stolper received options to purchase 1,000,000 shares of our common stock and Mr. James received options to purchase 1,500,000 shares of our common stock. The options have an exercise price equal to the closing price of our stock on May 17, 2007, and they vest one third each year over three years. Mr. Stolper and Mr. James agreed to serve as directors without any cash compensation.
Mark Stolper is the Chief Financial Officer of RadNet, Inc., a NASDAQ-listed leading owner and operator of medical diagnostic imaging centers. From January 2001 to July 2004, Mr. Stolper was a partner at Broadstream Capital Partners and West Coast Capital, Los Angeles-based investment banking firms focused on advising middle market companies engaged in financing and merger and acquisition transactions. Prior to joining Broadstream, Mr. Stolper was responsible for business development and mergers and acquisitions for Eastman Kodak's entertainment companies and its online image licensing business, Picture Network International. Mr. Stolper has also served as a member of Archon Capital Partners, Dillon, Read & Co., Inc., and Saratoga Partners, LLP. Mr. Stolper graduated magna ### laude from the University of Pennsylvania and received a finance degree from the Wharton School.
Simon James is a consultant to Oaktree Capital Management, LLC, Principal Opportunities Funds. Prior to joining Oaktree in January 2005, Mr. James was an Associate Principal with McKinsey & Company, Inc., where he was responsible for developing, negotiating and leading complex strategic and operational turnarounds in a broad range of industries. Mr. James received a PhD in finance and a bachelors degree in Natural Science from Cambridge University.
Aus einem US-Board: To quote from RadNet's Web Page (where our new Director, Mark Stolper
is C.F.O.):
"RadNet offers to its patients and referring physicians the full spectrum of diagnostic imaging exams, including PET/CT, MRI, CT, Nuclear Medicine, Mammography, Ultrasound and X-ray, as well as numerous other procedures. RadNet utilizes best of breed technology to appropriately serve the medical communities in which it operates.
Additionally, RadNet currently provides diagnostic imaging services to over 750,000 lives under exclusive capitation contracts with prominent medical groups and Independent Physician Groups (IPAs).
RadNet performs over 2.5 million diagnostic radiology and imaging procedures annually."
I'm sure the EKG & OSTEO programs can easily be integrated into RadNet's operation.
Mal schaun ob ich Alleinunterhalte bleibe
.Last Trade: 0.36
Trade Time: 3:35PM ET
Change: 0.08 (28.57%)
Prev Close: 0.28
Open: 0.28
Bid: 0.35 x 5000
Ask: 0.36 x 5000
1y Target Est: N/A
Day's Range: 0.28 - 0.37
52wk Range: 0.22 - 0.56
Volume: 592,990
Avg Vol (3m): 33,198.5
Market Cap: 8.86M
P/E (ttm): N/A
EPS (ttm): -0.03
Div & Yield: N/A (N/A)
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On May 17, 2007, we entered into a Side Letter Agreement with Boston Avenue Capital, LLC, amending the Securities Purchase Agreement between Boston Avenue Capital and us dated March 12, 2007. Under the terms of the Side Letter Agreement, within six months of the closing, Boston Avenue Capital has the right to recommend up to two nominees to be members of our Board of Directors.
Subject to the approval of the Board of Directors, the nominees shall be elected to serve a term of up to two years, after which, the Board of Directors may nominate them to be elected by the shareholders at the annual shareholder meeting in the same manner as any other director.
On May 17, 2007, we entered into an Agreement with Boston Avenue Capital, LLC.
The Agreement provides that Boston Avenue Capital and its affiliates will vote all of its stock in favor of the current Board of Directors for a period of five years.
On May 17, 2007, in connection with the Side Letter Agreement, the Board of Directors appointed Mr. Mark Stolper and Mr. Simon James as Directors. We intend for our new Board members to serve until their successors are duly nominated and elected.
As compensation for joining the Board of Directors, Mr. Stolper received options to purchase 1,000,000 shares of our common stock and Mr. James received options to purchase 1,500,000 shares of our common stock. The options have an exercise price equal to the closing price of our stock on May 17, 2007, and they vest one third each year over three years. Mr. Stolper and Mr. James agreed to serve as directors without any cash compensation.
Mark Stolper is the Chief Financial Officer of RadNet, Inc., a NASDAQ-listed leading owner and operator of medical diagnostic imaging centers. From January 2001 to July 2004, Mr. Stolper was a partner at Broadstream Capital Partners and West Coast Capital, Los Angeles-based investment banking firms focused on advising middle market companies engaged in financing and merger and acquisition transactions. Prior to joining Broadstream, Mr. Stolper was responsible for business development and mergers and acquisitions for Eastman Kodak's entertainment companies and its online image licensing business, Picture Network International. Mr. Stolper has also served as a member of Archon Capital Partners, Dillon, Read & Co., Inc., and Saratoga Partners, LLP. Mr. Stolper graduated magna ### laude from the University of Pennsylvania and received a finance degree from the Wharton School.
Simon James is a consultant to Oaktree Capital Management, LLC, Principal Opportunities Funds. Prior to joining Oaktree in January 2005, Mr. James was an Associate Principal with McKinsey & Company, Inc., where he was responsible for developing, negotiating and leading complex strategic and operational turnarounds in a broad range of industries. Mr. James received a PhD in finance and a bachelors degree in Natural Science from Cambridge University.
Aus einem US-Board: To quote from RadNet's Web Page (where our new Director, Mark Stolper
is C.F.O.):
"RadNet offers to its patients and referring physicians the full spectrum of diagnostic imaging exams, including PET/CT, MRI, CT, Nuclear Medicine, Mammography, Ultrasound and X-ray, as well as numerous other procedures. RadNet utilizes best of breed technology to appropriately serve the medical communities in which it operates.
Additionally, RadNet currently provides diagnostic imaging services to over 750,000 lives under exclusive capitation contracts with prominent medical groups and Independent Physician Groups (IPAs).
RadNet performs over 2.5 million diagnostic radiology and imaging procedures annually."
I'm sure the EKG & OSTEO programs can easily be integrated into RadNet's operation.
Trading Spotlight
Wenn das so weiter ginge ..... . Da ich Alleinunterhalter bin, kann ich meine Kursziele auch für mich behalten. Wenn jetzt die beiden Neuen noch mit guten Geschäften glänzen, dann wird aus Compumed noch ein Überflieger - Meine Meinung.
COMPUMED INC (OTC BB:CMPD.OB)
Last Trade: 0.49 Trade Time: 3:59PM ET
Change: 0.13 (36.11%)
Prev Close: 0.36
Open: 0.36
Bid: 0.49 x 5000
Ask: 0.50 x 5000
1y Target Est: N/A
Day's Range: 0.36 - 0.54
52wk Range: 0.22 - 0.56
Volume: 557,241 Avg Vol (3m): 41,037.3
Market Cap: 12.07M
P/E (ttm): N/A
EPS (ttm): -0.03
Div & Yield: N/A (N/A)
. Da ich Alleinunterhalter bin, kann ich meine Kursziele auch für mich behalten. Wenn jetzt die beiden Neuen noch mit guten Geschäften glänzen, dann wird aus Compumed noch ein Überflieger - Meine Meinung. COMPUMED INC (OTC BB:CMPD.OB)
Last Trade: 0.49 Trade Time: 3:59PM ET
Change: 0.13 (36.11%)
Prev Close: 0.36
Open: 0.36
Bid: 0.49 x 5000
Ask: 0.50 x 5000
1y Target Est: N/A
Day's Range: 0.36 - 0.54
52wk Range: 0.22 - 0.56
Volume: 557,241 Avg Vol (3m): 41,037.3
Market Cap: 12.07M
P/E (ttm): N/A
EPS (ttm): -0.03
Div & Yield: N/A (N/A)
Interessantes Posting aus einem US-Board von heute:
Let's Review The Situation...
CMPD has 2 businesses: EKG & OSTEO.
EKG makes money & is positioned to make more going forward, with
additional contracts for new over-reads.
OSTEO is just beginning to earn real money, with many options available to satisfy a (hopefully) burgeoning need.
OSTEO is FDA approved and has a Medicare Reimbursable Code assigned.
OSTEO is CE approved for European distribution.
OSTEO has patents for the process with Osteoarthritis approval pending.
OSTEO is currently available as a standalone product and as a CR & DICOM add-on.
It will soon be released as a combo MAMMO / OSTEO test along with a
remote pay per scan, web based evaluation (Osteo-Click).
CMPD has major distribution agreements for Osteoporosis with Kodak (now Carestream Health) in USA & China, FUJI USA and SwissRay in Europe.
It seems that something is in the works with MEDSTRAT for the forthcoming Osteoarthritis testing.
In addition, it has been hinted that CMPD will link up with a Pharma for the combined testing,
dosing and monitoring of Osteoarthritis (maybe even Osteoporosis as well).
CMPD has effectively sold 1/3rd of the Company to Boston Avenue Capital, a Hedge Fund ("...a recognized leader of fund administration with extensive experience in using sophisticated investment strategies...").
Originally, Boston Capital was to attend & observe Board Meetings for 6 months before requesting election to
The Board.
After only 1 month, they have sped up the process and have placed 2 new directors on The Board.
One is from Oaktree Capital Management (I assume a business partner of Boston Capital) and the other is from RADNET, "...the largest national owner of fixed-site diagnostic imaging centers...").
Both of these Directors have received options ("... they vest one third each year over three years...")
in lieu of direct pay (giving them a great incentive to perform).
Couple all of this with the fact that Medicare has cut reimbursements for expensive tests such as DEXA
and is emphasizing cheaper ones such as CMPD's.
The HMO's won't be far behind, I'm sure.
The Baby Boomers are starting to reach retirement and will be requiring more initial testing and follow-ups.
The whole Hospital System is in a crisis mode, with so many uninsured patients (both young & old) and forced to do basic screening for little (Medicaid) or no reimbursement at all.
More and more remote evaluations will have to be done to minimize the loss (or maximize the little profit).
More and more areas will have fewer and fewer doctors (particularly radiologists) to treat patients
(with or without insurance).
Hence, the need for remote evaluations, at a reasonable cost.
Ladies & Gentlemen of this Message Board I Ask You This:
Am I Dumb, Or Is This A No Brainer?
If It Doesn't Happen Now, Then It Will Never Happen.
Let's Review The Situation...
CMPD has 2 businesses: EKG & OSTEO.
EKG makes money & is positioned to make more going forward, with
additional contracts for new over-reads.
OSTEO is just beginning to earn real money, with many options available to satisfy a (hopefully) burgeoning need.
OSTEO is FDA approved and has a Medicare Reimbursable Code assigned.
OSTEO is CE approved for European distribution.
OSTEO has patents for the process with Osteoarthritis approval pending.
OSTEO is currently available as a standalone product and as a CR & DICOM add-on.
It will soon be released as a combo MAMMO / OSTEO test along with a
remote pay per scan, web based evaluation (Osteo-Click).
CMPD has major distribution agreements for Osteoporosis with Kodak (now Carestream Health) in USA & China, FUJI USA and SwissRay in Europe.
It seems that something is in the works with MEDSTRAT for the forthcoming Osteoarthritis testing.
In addition, it has been hinted that CMPD will link up with a Pharma for the combined testing,
dosing and monitoring of Osteoarthritis (maybe even Osteoporosis as well).
CMPD has effectively sold 1/3rd of the Company to Boston Avenue Capital, a Hedge Fund ("...a recognized leader of fund administration with extensive experience in using sophisticated investment strategies...").
Originally, Boston Capital was to attend & observe Board Meetings for 6 months before requesting election to
The Board.
After only 1 month, they have sped up the process and have placed 2 new directors on The Board.
One is from Oaktree Capital Management (I assume a business partner of Boston Capital) and the other is from RADNET, "...the largest national owner of fixed-site diagnostic imaging centers...").
Both of these Directors have received options ("... they vest one third each year over three years...")
in lieu of direct pay (giving them a great incentive to perform).
Couple all of this with the fact that Medicare has cut reimbursements for expensive tests such as DEXA
and is emphasizing cheaper ones such as CMPD's.
The HMO's won't be far behind, I'm sure.
The Baby Boomers are starting to reach retirement and will be requiring more initial testing and follow-ups.
The whole Hospital System is in a crisis mode, with so many uninsured patients (both young & old) and forced to do basic screening for little (Medicaid) or no reimbursement at all.
More and more remote evaluations will have to be done to minimize the loss (or maximize the little profit).
More and more areas will have fewer and fewer doctors (particularly radiologists) to treat patients
(with or without insurance).
Hence, the need for remote evaluations, at a reasonable cost.
Ladies & Gentlemen of this Message Board I Ask You This:
Am I Dumb, Or Is This A No Brainer?
If It Doesn't Happen Now, Then It Will Never Happen.
Keine weiteren News! It makes me wonder. Take a look at the volume!
Have a nice evening.
Last Trade: 0.72
Trade Time: 3:58PM ET
Change: 0.23 (46.94%)
Prev Close: 0.49
Open: 0.51
Bid: 0.71 x 2500
Ask: 0.73 x 2500
Day's Range: 0.49 - 0.75
52wk Range: 0.22 - 0.56
Volume: 1,341,691
Avg Vol (3m): 56,167.6
Market Cap: 17.73M
P/E (ttm): N/A
EPS (ttm): -0.03
Div & Yield: N/A (N/A
Have a nice evening.
Last Trade: 0.72
Trade Time: 3:58PM ET
Change: 0.23 (46.94%)
Prev Close: 0.49
Open: 0.51
Bid: 0.71 x 2500
Ask: 0.73 x 2500
Day's Range: 0.49 - 0.75
52wk Range: 0.22 - 0.56
Volume: 1,341,691
Avg Vol (3m): 56,167.6
Market Cap: 17.73M
P/E (ttm): N/A
EPS (ttm): -0.03
Div & Yield: N/A (N/A
liest sich grundsätzlich erstmal interessant.
dann erläutere doch mal deine kursziele
die bewertung hat immerhin in den letzten tagen um 10 millionen $ zugelegt, die bisherigen finanzkennzahlen rechtfertigen das kein bischen...
du gehst davon aus, dass durch die vertriebsallianz mit radnet die umsätze signifikant ansteigen, gell?!
dann erläutere doch mal deine kursziele
die bewertung hat immerhin in den letzten tagen um 10 millionen $ zugelegt, die bisherigen finanzkennzahlen rechtfertigen das kein bischen...
du gehst davon aus, dass durch die vertriebsallianz mit radnet die umsätze signifikant ansteigen, gell?!
Antwort auf Beitrag Nr.: 29.538.887 von Gulliver am 30.05.07 13:22:07Ich bin nicht mehr allein! Vergiss die Bilanzkennzahlen, Gulliver. Es geht hier um das Potential (Osteo und EKG), das in Compumed schlummert. Der Private Equity Fund hat dies anscheinend erkannt. Das Problem mit Compumed in der Vergangenheit war das unfähige Management. Der erste Schritt mit den zwei Neuen an Board ist getan. Ein Wichtiger und Du hast ja gesehen, was nach Bekanntgabe dieser News letzte Woche passiert ist. Was mich ein wenig wundert, war gestern nachmittag der signifikante Anstieg auf 0,72 US$; es wurde gekauft.
Selbstverständlich ist die Vertriebsallianz eine Option. Auch ein Buyout ist nicht auszuschließen. Kursziele sind immer so eine Sache. Gibt es gute News, Veträge usw. wird der Kurs auch anziehen. Lassen wir uns doch einfach positiv überraschen.
Sollte es gleich wieder nach oben gehen (Richtung 1 $), werde ich aber einen Teil meiner Position verkaufen und die Gewinne laufen lassen (Wir reden hier über einen Penny Stock).
Selbstverständlich ist die Vertriebsallianz eine Option. Auch ein Buyout ist nicht auszuschließen. Kursziele sind immer so eine Sache. Gibt es gute News, Veträge usw. wird der Kurs auch anziehen. Lassen wir uns doch einfach positiv überraschen.
Sollte es gleich wieder nach oben gehen (Richtung 1 $), werde ich aber einen Teil meiner Position verkaufen und die Gewinne laufen lassen (Wir reden hier über einen Penny Stock).
Interessantes Posting aus einem US-Board, insbesonders was den gestrigen Handelstag (29.5.2007) anging:
So tired of the cheerleading speculation on this board but I will yield to it any way
FACT:
We have been disappointed by these periodic run-ups more than 10 times in the 15+ years I've been following this stock. But here's why yesterday's activity might be a little different:
FACT:
Yesterday's trade volume of 1.3 million shares is one of the 10 largest days of trading in this stock in the LAST 20 YEARS.
FACT:
Yesterday's trading volume was the single largest trade volume IN OVER 8 YEARS.
FACT:
Yesterday's close ($.72) broke through the previous 52 week high by OVER 25%.
SPECULATION:
The combination of the incredibly large trading volume (over 20X the previous daily average) and the high price leaves a lot of buyers with a break-even at well over $.50 and thus a speculative run-up for them could be in the $1.50 to $2 range.
This perceived alliance with a previously acquisitve RADNET ( They just purchased Radiologic?) could lead to an alliance that actually provides the end user some value. CMPD's superior low cost technology and Radnet's massive imaging center distribution channel.
QUESTION:
Other than one board seat being filled by a gentleman from Radnet, nothing else has been announced right? No distribution agreement, no additional sales, no alliance.
SPECULATION:
That Radnet might see the light of the huge commercial upside of the detoxahol serum and that truly gives this stock the huge upside.
Napkins out! It's time to dine on the fruits of our previous futility.
So tired of the cheerleading speculation on this board but I will yield to it any way
FACT:
We have been disappointed by these periodic run-ups more than 10 times in the 15+ years I've been following this stock. But here's why yesterday's activity might be a little different:
FACT:
Yesterday's trade volume of 1.3 million shares is one of the 10 largest days of trading in this stock in the LAST 20 YEARS.
FACT:
Yesterday's trading volume was the single largest trade volume IN OVER 8 YEARS.
FACT:
Yesterday's close ($.72) broke through the previous 52 week high by OVER 25%.
SPECULATION:
The combination of the incredibly large trading volume (over 20X the previous daily average) and the high price leaves a lot of buyers with a break-even at well over $.50 and thus a speculative run-up for them could be in the $1.50 to $2 range.
This perceived alliance with a previously acquisitve RADNET ( They just purchased Radiologic?) could lead to an alliance that actually provides the end user some value. CMPD's superior low cost technology and Radnet's massive imaging center distribution channel.
QUESTION:
Other than one board seat being filled by a gentleman from Radnet, nothing else has been announced right? No distribution agreement, no additional sales, no alliance.
SPECULATION:
That Radnet might see the light of the huge commercial upside of the detoxahol serum and that truly gives this stock the huge upside.
Napkins out! It's time to dine on the fruits of our previous futility.
Die 50 hat gehalten. Das war doch schon mal was. Vorgestern ist die Aktie von 0.49 auf 0.72 gestiegen. Das heisst es wurde gekauft. Ich hoffe, daß in Kürze weitere News folgen. Da wird man sehen was mit Compumed passiert.
Volumen läßt erwartungsgemäß nach. Die Unterstützung hält. Schlusskurs 0,60 $. Bin auf die nächste News gespannt. Diesmal könnte es tatsächlich etwas mit Compumed werden.
Schönes Wochenende
Schönes Wochenende
Der nächste Personalwechsel: (aus einem US-Board)
On June 1, 2007, we received a notice of resignation from our Chief Executive Officer, John G. McLaughlin effective that day. That notice was accepted by the Chairman of the Board, Robert Stuckelman on June 4th, 2007.
Effective June 1, 2007, we appointed Maurizio Vecchione to the position of Interim Chief Executive Officer. We will amend our Contractor Agreement with Synthetica (America), Ltd. to provide the services of Mr. Vecchione in this capacity. Under the terms of the Amendment, Mr. Vecchione, while part-time, will spend sufficient time at the Company to discharge the duties needed of the CEO.
Maurizio Vecchione is a Managing Partner of Synthetica Holdings, LLC, a private equity and venture fund, and the Chairman of Synthetica (America) Ltd., a management consultant retained to provide strategic advice to Compumed. Mr. Vecchione joined Synthetica in September 2001. He also serves as Chairman of The IDEAS Studio, a multimedia content company in the educational field and Interim CEO of Mobile Video Development Corporation, an early stage company in wireless video technology. From July 2004 to September 2006 Mr. Vecchione served as CEO of Trestle Holdings, Inc, a medical imaging company for digital pathology and a company for which he orchestrated a restructuring and the sale of its operating assets. From April 2003 to July 2004 Mr. Vecchione was President and CEO of Microwave Photonics, a wireless technology company he spun out of British Telecommunications. Prior to joining Microwave he was the founder and co-CEO of imaging rendering company ModaCAD (later Styleclick) and lead the company from 1983 through 2001, when he orchestrated its sale to USA Networks (now InterActive) for approximately $480 Million.
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx…
Our New C.E.O....
h t t p://w w w.syntheticaltd.c o m/pages/708646/index.htm
(remove spaces to view home page)
Mr. Vecchione has a 20 years career as a senior executive of high technology companies, with a significant track record of shareholder value creation.
He was responsible for multiple IPO’s, raised over $100M in equity capital, and was involved in multiple merger & acquisitions transactions in both public and private companies, with over $1B in aggregate transaction value.
Mr. Vecchione’s career focus has been early stage, high growth technology companies in software (content management, graphics and imaging, electronic commerce), wireless telecommunications, components and systems.
He has focused on companies undergoing significant strategic transactions, or strategic re-capitalizations and turn-arounds. Mr. Vecchione is Chairman of Synthetica, a private equity fund and management consultant specializing in turnaround investments.
He is also Chief Executive Officer of Trestle Holdings, Inc. a public developer of imaging systems for drug discovery, drug safety and tissue pathology informatics in clinical and pharmaceutical applications.
He is also the Chairman of The IDEA Studio Inc., a developer of educational enrichment programs and software for children pre-K to 6th grade.
He was previously the CEO of Microwave Photonics, Inc. a company which he span out of British Telecommunications and commercializing a disruptive wireless switching technology for high speed wireless telecommunications.
Prior, Mr. Vecchione was the CEO of Styleclick Inc., then a public technology company developing advanced computer graphics applications for content management and visual merchandising.
He joined the company in 1988, then operating under the name ModaCAD and focused on a proprietary rendering imaging solution; In 1989 Mr. Vecchione raised multiple rounds of private equity funding;
In 1996 he led the Company’s public offering, and in the following years, Mr. Vecchione helped guide the company’s growth to over $500M in market capitalization.
In 1999 Mr. Vecchione helped orchestrate a strategic capitalization of the company with UBS/Paine Webber, ING and Intel Corporation; subsequently Intel became the largest shareholder and the company’s name was changed to Styleclick; in 2000, he helped architect a $480M stock and cash strategic sale of the company to Interactive Corp, (then USA Networks Inc.), one of the largest media companies in the world.
As part of the transaction, Styleclick also acquired the assets of the Internet Shopping Network, a pioneer of electronic commerce and a subsidiary of USA Networks.
Subsequent to the transaction, and until early 2001, Mr. Vecchione was the CEO of the USA Networks public subsidiary that resulted from the strategic transaction.
In his career, Mr. Vecchione has been instrumental in fostering and managing strategic relationships with Intel, GE, Philips, Siemens, Hachette Filipacchi, Viacom, Universal-Vivendi as well as NTT DoCoMo, British Telecom, Verizon, AT&T and Nokia among others.
As part of his work with British Telecommunications, he has helped create exploitation routes to the Company\'s vast intellectual properties and disruptive technologies.
Prior to 1988, Mr. Vecchione held various positions with Tektronix Corporation, the world leader in test, measurement and monitoring instrumentation; CAECO, a pioneer of graphics systems used in the design of the electronic integrated circuits; Photomatrix, a pioneer in imaging and opto-electronic systems; and PSS, a diversified defense contractor.
In those positions, he was involved in developing imaging products, hardware components including semiconductors, electronic components, software and systems.
Mr. Vecchione is trained as a physicist and has a distinguished career in science research prior to entering industry, including work for NASA and CERN, where he was involved in the early development of computer graphics and the world wide web.
Mr. Vecchione was nominated twice Ernst & Young Entrepreneur of the year, and some of his companies were named Fast 50 companies in 1999 and 2000 by Deloitte & Touche. In 2002 he was awarded the “Corporate Innovation” award by British Telecommunications.
He is a frequent speaker on business and technology issues and has been featured in the Wall Street Journal, Business Week, Financial Times, Forbes and has appeared on CNN/fn, CNBC, Bloomberg and many other national press and programs.
On June 1, 2007, we received a notice of resignation from our Chief Executive Officer, John G. McLaughlin effective that day. That notice was accepted by the Chairman of the Board, Robert Stuckelman on June 4th, 2007.
Effective June 1, 2007, we appointed Maurizio Vecchione to the position of Interim Chief Executive Officer. We will amend our Contractor Agreement with Synthetica (America), Ltd. to provide the services of Mr. Vecchione in this capacity. Under the terms of the Amendment, Mr. Vecchione, while part-time, will spend sufficient time at the Company to discharge the duties needed of the CEO.
Maurizio Vecchione is a Managing Partner of Synthetica Holdings, LLC, a private equity and venture fund, and the Chairman of Synthetica (America) Ltd., a management consultant retained to provide strategic advice to Compumed. Mr. Vecchione joined Synthetica in September 2001. He also serves as Chairman of The IDEAS Studio, a multimedia content company in the educational field and Interim CEO of Mobile Video Development Corporation, an early stage company in wireless video technology. From July 2004 to September 2006 Mr. Vecchione served as CEO of Trestle Holdings, Inc, a medical imaging company for digital pathology and a company for which he orchestrated a restructuring and the sale of its operating assets. From April 2003 to July 2004 Mr. Vecchione was President and CEO of Microwave Photonics, a wireless technology company he spun out of British Telecommunications. Prior to joining Microwave he was the founder and co-CEO of imaging rendering company ModaCAD (later Styleclick) and lead the company from 1983 through 2001, when he orchestrated its sale to USA Networks (now InterActive) for approximately $480 Million.
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx…
Our New C.E.O....
h t t p://w w w.syntheticaltd.c o m/pages/708646/index.htm
(remove spaces to view home page)
Mr. Vecchione has a 20 years career as a senior executive of high technology companies, with a significant track record of shareholder value creation.
He was responsible for multiple IPO’s, raised over $100M in equity capital, and was involved in multiple merger & acquisitions transactions in both public and private companies, with over $1B in aggregate transaction value.
Mr. Vecchione’s career focus has been early stage, high growth technology companies in software (content management, graphics and imaging, electronic commerce), wireless telecommunications, components and systems.
He has focused on companies undergoing significant strategic transactions, or strategic re-capitalizations and turn-arounds. Mr. Vecchione is Chairman of Synthetica, a private equity fund and management consultant specializing in turnaround investments.
He is also Chief Executive Officer of Trestle Holdings, Inc. a public developer of imaging systems for drug discovery, drug safety and tissue pathology informatics in clinical and pharmaceutical applications.
He is also the Chairman of The IDEA Studio Inc., a developer of educational enrichment programs and software for children pre-K to 6th grade.
He was previously the CEO of Microwave Photonics, Inc. a company which he span out of British Telecommunications and commercializing a disruptive wireless switching technology for high speed wireless telecommunications.
Prior, Mr. Vecchione was the CEO of Styleclick Inc., then a public technology company developing advanced computer graphics applications for content management and visual merchandising.
He joined the company in 1988, then operating under the name ModaCAD and focused on a proprietary rendering imaging solution; In 1989 Mr. Vecchione raised multiple rounds of private equity funding;
In 1996 he led the Company’s public offering, and in the following years, Mr. Vecchione helped guide the company’s growth to over $500M in market capitalization.
In 1999 Mr. Vecchione helped orchestrate a strategic capitalization of the company with UBS/Paine Webber, ING and Intel Corporation; subsequently Intel became the largest shareholder and the company’s name was changed to Styleclick; in 2000, he helped architect a $480M stock and cash strategic sale of the company to Interactive Corp, (then USA Networks Inc.), one of the largest media companies in the world.
As part of the transaction, Styleclick also acquired the assets of the Internet Shopping Network, a pioneer of electronic commerce and a subsidiary of USA Networks.
Subsequent to the transaction, and until early 2001, Mr. Vecchione was the CEO of the USA Networks public subsidiary that resulted from the strategic transaction.
In his career, Mr. Vecchione has been instrumental in fostering and managing strategic relationships with Intel, GE, Philips, Siemens, Hachette Filipacchi, Viacom, Universal-Vivendi as well as NTT DoCoMo, British Telecom, Verizon, AT&T and Nokia among others.
As part of his work with British Telecommunications, he has helped create exploitation routes to the Company\'s vast intellectual properties and disruptive technologies.
Prior to 1988, Mr. Vecchione held various positions with Tektronix Corporation, the world leader in test, measurement and monitoring instrumentation; CAECO, a pioneer of graphics systems used in the design of the electronic integrated circuits; Photomatrix, a pioneer in imaging and opto-electronic systems; and PSS, a diversified defense contractor.
In those positions, he was involved in developing imaging products, hardware components including semiconductors, electronic components, software and systems.
Mr. Vecchione is trained as a physicist and has a distinguished career in science research prior to entering industry, including work for NASA and CERN, where he was involved in the early development of computer graphics and the world wide web.
Mr. Vecchione was nominated twice Ernst & Young Entrepreneur of the year, and some of his companies were named Fast 50 companies in 1999 and 2000 by Deloitte & Touche. In 2002 he was awarded the “Corporate Innovation” award by British Telecommunications.
He is a frequent speaker on business and technology issues and has been featured in the Wall Street Journal, Business Week, Financial Times, Forbes and has appeared on CNN/fn, CNBC, Bloomberg and many other national press and programs.
Man wartet auf weitere News. Die Aktie notiert um die 0.65 US$.
Immer noch keine News, aber der Kurs steht bei 0,71. Bin gespannt auf die nächste News - eigentlich kann es nur aufwärts gehen
.
Bin gespannt auf die nächste News - eigentlich kann es nur aufwärts gehen
.
Compumed will neue Aktien ausgeben. Shareholder Meeting ist Ende August. Ich bin (vorerst) ausgestiegen, weil mir die Anzahl der Aktien zu hoch hoch erscheint.
Hier kann man das nachlesen (1.Zeile)
http://yahoo.brand.edgar-online.com/default.aspx?cik=700998
REASON FOR AND GENERAL EFFECT OF INCREASING AUTHORIZED COMMON STOCK (von einem US-Board)
Our Amended Certificate of Incorporation, as amended, currently authorizes us to issue 50,000,000 shares of common stock. As of July 3, 2007, we had 24,827,037 shares of common stock issued and outstanding. We believe we need to increase our authorized shares of common stock available for issuance by the Company so that we can better support future growth plans and opportunities. An increase in the authorized number of shares of common stock will enable us to take advantage of various potential business opportunities through the issuance of our securities, including, without limitation, issuing stock dividends to existing stockholders, establishing certain strategic relationships with other companies, expand our business through acquisitions, enter into joint ventures, sell stock to investors to increase available capital and provide equity incentives to employees, officers or directors. We have no present agreements or definitive plans to enter into any such transactions or to acquire any businesses.
Hier kann man das nachlesen (1.Zeile)
http://yahoo.brand.edgar-online.com/default.aspx?cik=700998
REASON FOR AND GENERAL EFFECT OF INCREASING AUTHORIZED COMMON STOCK (von einem US-Board)
Our Amended Certificate of Incorporation, as amended, currently authorizes us to issue 50,000,000 shares of common stock. As of July 3, 2007, we had 24,827,037 shares of common stock issued and outstanding. We believe we need to increase our authorized shares of common stock available for issuance by the Company so that we can better support future growth plans and opportunities. An increase in the authorized number of shares of common stock will enable us to take advantage of various potential business opportunities through the issuance of our securities, including, without limitation, issuing stock dividends to existing stockholders, establishing certain strategic relationships with other companies, expand our business through acquisitions, enter into joint ventures, sell stock to investors to increase available capital and provide equity incentives to employees, officers or directors. We have no present agreements or definitive plans to enter into any such transactions or to acquire any businesses.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,69 | |
| -0,02 | |
| -1,50 | |
| -2,40 | |
| -0,17 | |
| -0,74 | |
| -2,78 | |
| -2,50 | |
| +0,04 | |
| +0,01 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 229 | ||
| 108 | ||
| 104 | ||
| 68 | ||
| 57 | ||
| 41 | ||
| 39 | ||
| 37 | ||
| 37 | ||
| 35 |
